

**AD-A279 196****CUMENTATION PAGE**Form Approved  
OMB No. 0704-0188**(2)**

ation is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson 02, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

<b>2. REPORT DATE</b> 1994		<b>3. REPORT TYPE AND DATES COVERED</b> Journal article	
<b>4. TITLE AND SUBTITLE</b> Correction of the enzyme deficiency in hematopoietic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol		<b>5. FUNDING NUMBERS</b>  PE -63706 PR -M0095 TA - 003 WU -1007	
<b>6. AUTHOR(S)</b> Xu L, Stahl SK, Dave HP, Schiffmann R, Correll PH, Kessler, Karlsson S			
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Naval Medical Research Institute Commanding Officer 8901 Wisconsin Avenue Bethesda, Maryland 20889-5607		<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>  NMRI 94-11	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> Naval Medical Research and Development Command National Naval Medical Center Building 1, Tower 12 8901 Wisconsin Avenue Bethesda, Maryland 20889-5606		<b>10. SPONSORING/MONITORING AGENCY REPORT NUMBER</b>  DN677130	
<b>11. SUPPLEMENTARY NOTES</b>  Reprinted from: Experimental Hematology 1994 Vol.22 pp.223-230			
<b>12a. DISTRIBUTION/AVAILABILITY STATEMENT</b>  Approved for public release; distribution is unlimited.		<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 words)</b>  <div style="text-align: center;"><b>DTIC</b> <b>ELECTE</b> <b>MAY 16 1994</b> <b>S-B-D</b></div>			
<b>14. SUBJECT TERMS</b>  Gene therapy, CD34+, stem cells, GC deficiency, Gaucher disease, retroviral supernatant, transduction		<b>15. NUMBER OF PAGES</b> 8	
		<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited


NSN 7540-01-280-5500

Standard Form 298 (Rev 2-89)  
Prescribed by ANSI Std Z39-18  
298-102**DTIC QUALITY INSPECTED 1**

**Best  
Available  
Copy**

Rapid Communication

# Correction of the enzyme deficiency in hematopoietic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol\*



Licheng Xu,<sup>1</sup> Stephanie K. Stahl,<sup>1</sup> Harish P.G. Dave,<sup>1</sup> Raphael Schiffmann,<sup>1</sup> Pamela H. Correll,<sup>1</sup> Steven Kessler,<sup>2</sup> Stefan Karlsson<sup>1</sup>

<sup>1</sup>Molecular and Medical Genetics Section, Developmental and Metabolic Neurology Branch, NINDS;

<sup>2</sup>Immune Cell Biology Program, Naval Medical Research Institute, Bethesda, MD

Offprint requests to: Licheng Xu, MD, PhD, Molecular and Medical Genetics Section, Developmental and Metabolic Neurology Branch, NINDS, National Institutes of Health, Building 10, Room 3D04, Bethesda, MD 20892

(Received 22 October 1993; accepted 14 November 1993)

\*This study was in part supported by a grant of the National Gaucher Foundation to S. Karlsson. S. Kessler was supported in part by Naval Medical Research and Development Command, Work Unit No. M0095.003.1007. The opinions and assertions contained herein are the private ones of the writers and are not to be construed as official or reflecting the views of the Navy Department or the Naval Service at large.

## Abstract

Gaucher disease is a lysosomal storage disorder caused by a deficiency of the enzyme glucocerebrosidase (GC), and is an excellent candidate for gene replacement therapy. To develop a clinically acceptable protocol for this purpose, we created two amplified (A) high-titer retroviral vector-producer cell lines to efficiently transduce hematopoietic stem and progenitor cells. GP+envAm12/A-LGSN (A-LGSN), contained the GC cDNA driven by the retroviral long terminal repeat (LTR) and the neomycin phosphotransferase gene expressed from the simian virus 40 early promoter. GP+envAm12/A-LG4 (A-LG4) contained only the GC gene driven by the LTR. Both A-LGSN and A-LG4 contained multiple-proviral copies and gave approximately 10-fold higher titers on 3T3 cells compared to their unamplified counterparts. These vectors were packaged in GP+envAm12 cells because vectors produced in this cell line transduced hematopoietic cells more efficiently than other packaging cells tested. Bone marrow mononuclear cells and purified CD34<sup>+</sup> cells were infected with virus supernatants four times in the presence of interleukin-3 (IL-3), IL-6, and stem cell factor (SCF) over 96 hours in culture. Cells were then plated in semisolid cultures and colony-forming unit-granulocyte/macrophage (CFU-GM) colonies were scored for vector presence by polymerase chain reaction (PCR). Transduction efficiency of CFU-GM colonies derived from CD34<sup>+</sup> cells was improved considerably using the amplified vectors in the GP+envAm12 packaging line. For A-LGSN, A-LG4, and unamplified LGSN, transduction efficiencies were 41, 42, and 25%, respectively. Therefore, multiple proviral copies resulting in higher titer improves retroviral transduction of human hematopoietic progenitor cells. Hematopoietic cells from Gaucher patients were transduced and placed into long-term bone marrow culture (LTBMC). Viral supernatant from the amplified producer lines transduced long-term culture initiating cells (LTCIC) efficiently (30 to 50%) using this clinically acceptable protocol. Both sustained mRNA expression and GC enzyme production are achieved in the long-term culture of LTCIC and lead to correction of the GC deficiency in their progeny cells.

**Key words:** GC deficiency—Gene therapy—Gaucher disease—Retroviral supernatant—Transduction


## Introduction


Gaucher disease is an autosomal recessive lysosomal storage disorder characterized by a deficiency of GC and an accumulation of glucocerebroside in bone marrow-derived macrophages [1]. A variety of clinical manifestations of this disease have been described, including hepatosplenomegaly, hypersplenism, pancytopenia, and bone deterioration [2]. Recently, enzyme replacement therapy [3-5] and allogeneic bone marrow transplantation [6,7] have offered promising therapeutic alternatives. However, enzyme replacement is an expensive intravenous therapy that must be continued throughout the patient's lifetime, and allogeneic bone marrow transplantation is associated with severe morbidity and mortality and cannot be applied universally [8]. Therefore, development of alternative therapeutic approaches is desirable.

Somatic cell gene therapy, delivery of a therapeutic gene into an abnormal cell, has already been used successfully in the treatment of ADA deficiency, and numerous clinical trials are underway [9-11]. In studies for Gaucher disease, the human GC gene has been transferred into hematopoietic progenitor cells [12,13] and hematopoietic stem cells (HSC) of mice [14-17]. Expression of potentially therapeutic levels of human GC enzyme was found in the majority of macrophages from long-term reconstituted mice transplanted with retrovirally transduced HSC [17,18]. In addition, retroviral-mediated transfer of normal human GC cDNA into CFU-GM hematopoietic progenitor cells from Gaucher patients has been demonstrated in a transient culture system; however, the enzyme deficiency could be corrected only after selection of the transduced cells due to poor expression of the transferred GC gene [19]. Most recently, Nolte et al. [20] employed a coculture transduction protocol to transfer the GC gene into more primitive hematopoietic progenitor cells of a Gaucher patient and demonstrated physiologically relevant enzyme expression in progeny cells 1 month after the transduction.

Coculture infection procedure was previously used for transfer of potentially therapeutic genes into human

94 5 13 047





**Fig. 1.** Retroviral vectors used for GC cDNA transfer. **A.** LG, a murine retrovirus-based vector that includes the GC cDNA driven by the MoMLV LTR. **B.** LGSN, a vector containing the GC cDNA driven by the LTR and the neomycin phosphotransferase gene (Neo) expressed from the simian virus 40 early promoter (Sv). SD = splicing donor; SA = splicing acceptor; pA = polyadenylation site; E = EcoRI; N = Nhe I; X = Xho I. Arrows indicate transcriptional start sites and direction of transcription.

hematopoietic cells because it was difficult to achieve efficient transduction of human hematopoietic cells by supernatant infection techniques. An innovative approach to improve transduction efficiency was presented by Moore et al. [21] using supernatant infection in the presence of stromal cells, but this can be cumbersome in a clinical setting. To develop a clinically acceptable protocol for efficient transfer of a therapeutic gene into primitive hematopoietic progenitor cells, we used two amplified retroviral producer cells (A-LG4 and A-LGSN) containing multiple vector copies to generate high-titer virus supernatant. Transduction efficiency of CD34<sup>+</sup> bone marrow cells was improved considerably using supernatants from the amplified producer cell lines, demonstrating that multiple viral copies in producer cells increase their ability to transduce human hematopoietic progenitors. These amplified supernatants were also tested for transduction of mononuclear bone marrow cells and CD34<sup>+</sup> bone marrow cells from Gaucher patients. Correction of enzyme activity was seen in the colonies 7 weeks (5 weeks in LTBMC and 2 weeks in CFU-GM assay) after the initial gene transfer procedure. We conclude that LTCIC from patients with Gaucher disease have been efficiently transduced and that correction of the GC enzyme deficiency in their progeny cells has been accomplished.

## Materials and methods

### Cell culture and retroviral vectors

Psi-CRIP and GP+envAm12 cells were maintained at 37°C in Dulbecco's modified Eagle's medium (DMEM) (DPBS; Biofluids, Rockville, MD) supplemented with 10% newborn calf serum (NCS-DM) (fetal bovine serum [FBS-DM] was used for PA317 cells), 100 U/mL penicillin, and 100 µg/mL streptomycin. The cells were passaged every third day after dislodgement with 0.05% trypsin/0.02% EDTA.

Retroviral vectors used in this study, LG and LGSN, were described previously by Correll et al. [18] and Freas et al. [22], respectively. Briefly, LGSN is a murine retrovirus-based

vector that includes GC cDNA driven by the LTR and the neomycin phosphotransferase gene expressed from the simian virus 40 early promoter, and LG contains only GC driven by the LTR (Fig. 1).

### Virus production

Superinfection of packaging cells was performed to obtain high-titer amphotropic vectors either by coculture [23,24] or by repeated supernatant infections. Amplified GP+envAm12/LGSN clones were obtained by coculturing amphotropic GP+envAm12/LGSN and ecotropic GP+E-86/LGSN for 12 days, during which period kinetics of virus production was measured to determine the optimal length of coculture. Subsequent determination of virus titer demonstrated that coculture of GP+envAm12/LGSN and GP+E-86/LGSN for 6 to 8 days could maximize virus production (Dave et al., unpublished observation).

To generate a high-titer LG vector, superinfection of GP+envAm12 cells was done by repeated application of ecotropic supernatant. Briefly, high-titer viral supernatant from GP+E-86 LG was collected and frozen at -80°C in 3- to 5-mL aliquots. GP+envAm12 packaging cells were split 1:10 and infected the following day with 3 mL GP+E-86/LG supernatant, 7 mL culture medium, and 8 µg/mL polybrene. Infection was repeated daily until cells became confluent. Confluent cells were split again and infected and the procedure was repeated until 12 infections were completed. Individual clones were obtained by plating 100 to 1000 cells on 10-cm culture dishes, and a total of 20 to 40 colonies were isolated. Clone 4 of A-LG (A-LG4) was used in the experiments. Viral titer was determined by infecting 3T3<sup>tk</sup> cells with 5 mL viral supernatant, and copy number of the provirus in these cells was determined by Southern blot analysis. Helper virus was detected by a marker rescue assay [25,26] using 3T3<sup>tk</sup> cells containing one copy of the LGSN vector. These cells were infected by the test supernatant, the cells were passaged for 2 weeks, and at that time their supernatant was tested for passage of virus on virgin 3T3<sup>tk</sup> cells.

**Ficoll-gradient separation of mononuclear BM (MNBM) cells**

Both normal and Gaucher type I bone marrows were voluntarily donated and harvested by needle aspiration from the posterior iliac crest after informed consent. Bone marrow was diluted 1:3 with 2% FBS-Iscove's medium (FBS-IM), and MNBM cells were obtained by Ficoll-gradient centrifugation at 400g at room temperature for 30 minutes on LSM lymphocyte separation medium (Organon Teknica-Cappel, Durham, NC). MNBM cells were washed twice using 2% FBS-IM followed by centrifugation at 1500 rpm for 10 minutes (Sorvall RT6000B). The cell pellet was resuspended either in 2% FBS-IM containing 1000 U/mL DNase I for isolation of CD34<sup>+</sup> cells or in LTBMC medium (HCC-5100 myeloid long-term culture medium; Terry Fox Laboratory, Vancouver, Canada) for retroviral infection.

**Isolation of BM CD34<sup>+</sup> cells**

CD34<sup>+</sup> cells from MNBM of normal donors and Gaucher patients were purified by positive immunoselection using the CD34 monoclonal antibody KG.1 linked to magnetic Dynabeads (DynaLink, Fort Lee, NJ) as described elsewhere [27].

**BM cell infection and LTBMC**

Supernatant infection of hematopoietic BM cells was performed as described by Hughes et al. [28] with modifications. MNBM and BM CD34<sup>+</sup> cells were infected at 37°C using fresh virus supernatant supplemented with 2 mM L-glutamine, 8 µg/mL polybrene or 4 µg/mL protamine sulfate, 20 ng/mL IL-3, 50 ng/mL IL-6, and 100 ng/mL SCF at 10<sup>6</sup> cells/mL and 2×10<sup>5</sup> cells/mL, respectively. Approximately 24 hours later, cells were centrifuged at 1000 rpm for 10 minutes and infected under the same conditions as above. The infection procedure was performed once daily for 4 consecutive days. At the end of infection, cells were sampled to determine infection efficiency, and the remaining cells were transferred into T25 ventilated flasks (Costar, Cambridge, MA) at initial densities of 10<sup>6</sup> cells/mL and 2×10<sup>5</sup> cells/mL for MNBM and BM CD34<sup>+</sup> cells, respectively, on irradiated feeder layers prepared from heterogenous BM [29] for LTBMC. Cells were maintained at 33°C for 5 weeks, during which time weekly 60% medium change was performed; cell samples were taken for clonogenic assays for CFU-GM and GC enzymatic assays at weeks 3 and 5.

**Clonogenic assays for CFU-GM**

MNBM and BM CD34<sup>+</sup> cells from postinfection cultures or LTBMC were assayed for clonogenic activity by plating 1 to 5×10<sup>4</sup> MNBM cells or 500 BM CD34<sup>+</sup> cells in 1 mL HCC-4200's Iscove's methylcellulose (Terry Fox) supplemented with 2 mM L-glutamine and 10 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF) in a 35-mm culture dish to yield 20 to 100 colonies empirically. When cells were taken from late stages of LTBMC, the number of cells plated was doubled. The culture was maintained at 33°C for 2 weeks. Well-isolated colonies were picked for detection of GC cDNA by PCR analysis, and the remainder of the colonies were pooled for GC enzyme assay.

**Detection of GC cDNA in CFU-GM by PCR**

Individual CFU-GM colonies were picked and suspended in cold DPBS and microcentrifuged for 20 to 30 seconds. Pellets were resuspended in 10 to 20 µL PCR preparation buffer with nonionic detergents and Proteinase K (50 mM KCl; 10 mM Tris-HCl, pH 8.3; 2.5 mM MgCl<sub>2</sub>; 0.1 mg/mL gelatin; 0.45% NP40; 0.45% Tween 20; and 60 µg/mL freshly prepared proteinase K) [30]. PCR samples were incubated at 55°C for 1 hour and inactivated at 95°C for 10 minutes. The sam-

ples were then used as templates for PCR amplification. Primers were located in GC exon 9 and exon 11 (GC9: ACT TTG TCG ACA GTC CCA TC; GC11: CGC CAC AGG TAG GTG TGA AT). AmpliTaq and reagents were purchased from Perkin Elmer Cetus (Norwalk, CT). PCR conditions were set as follows: initial denaturation at 94°C for 5 minutes; total 30 cycles of amplification; each cycle with denaturation (93°C, 1 minute 30 seconds), annealing (65°C, 2 minutes), and elongation (71°C, 1 minute 30 seconds with 2-second extension in each additional cycle); final reaction at 65°C for 4 minutes, 71°C for 8 minutes, and slowly cooling to room temperature. Amplified products were loaded on 1% agarose gels. At the end of electrophoresis, the gel was illuminated on ultraviolet and then blotted onto Nytran membrane for Southern blot analysis using <sup>32</sup>P-labeled GC cDNA probes.

**Northern blot analysis**

RNA extraction and hybridization conditions were as described elsewhere [31].

**GC enzymatic assay**


CFU-GM colonies were pooled from methylcellulose culture. Cell lysates were prepared as previously described [32]. Briefly, cells were harvested, suspended in 100 µL potassium citrate/potassium phosphate buffer (pH 5.9) containing Triton X-100 (2 mg/mL), and disrupted by three cycles of freezing-thawing in an ethanol-dry ice bath and a 37°C bath. The cellular extracts were centrifuged in an Eppendorf microcentrifuge for 15 minutes at 4°C. The supernatant was used for the GC assay [19] and for the assessment of protein [33].

**Giemsa and Wright staining of hematological slides**

Cultured cells (1 to 4×10<sup>4</sup> in 0.5 mL) were mounted on a slide by using Cytospin 3 (Shandon, Pittsburgh, PA). The slide was then stained with the aerospray hematology slide stainer 7100 (Wescor, Logan, UT).

**Results****Amplified high-titer viral producers improve transduction of hematopoietic cells**

Three amphotropic retrovirus packaging cell lines, PA317 [34], PsiCRIP [26], and GP-envAm12 [35,36] were used to produce the GC-containing retroviral vector, LGSN, for infection of 3T3<sup>tk-</sup> and BM CD34<sup>+</sup> cells. GP+envAm12 proved to be the most efficient to transduce hematopoietic cells and was used in all subsequent experiments. In an attempt to increase the viral titer of our vectors, we multiplied the proviral copy number within the GP+envAm12 packaging cells by repeated transductions of ecotopic vectors. A-LGSN vector was created by coculture of GP+envAm12/LGSN and GPE86/LGSN cells, and the A-LG4 producer cells were generated by repeated supernatant infection. Both producer clones contained more than five proviral copies as determined by Southern blot analysis (Figure 2). The copy number was determined by using an enzyme (*Nhe* I) that cuts the proviral DNA once and can distinguish between individual integration sites. The *Nhe* I that cuts both LTRs was also used to estimate the number of copies. The A-LGSN was titered on 3T3<sup>tk-</sup> cells and gave a titer of 1×10<sup>6</sup>, or approximately one order of magnitude higher than the single copy GP+envAm12/LGSN vector (1.5×10<sup>5</sup>). The A-LG4 vector could not be titered by G-18 resistance, but it did contain seven to eight proviral copies. When it was used to infect 3T3<sup>tk-</sup> cells, the viral copy number in the target cells was more than one per cell, similar to the A-LGSN. We therefore assumed that the A-LG4 vector had a similar titer to the



**Fig. 2.** A. Determination of proviral copy number (left) and integration number (right) of vector packaging cell lines. Genomic DNAs from GP+envAm12 (GPAm12) packaging cell lines were isolated and digested with *Nhe* I or *Xho* I. Digested DNA samples were fractionated in 1% agarose gel and transferred onto Nytran membrane, followed by Southern blot analysis. Plasmid/LG and plasmid/LGSN = mixed with genomic DNA and used as copy number control (copy/cell) as indicated; GPAm12/control = uninfected packaging cells; GPAm12/LGSN = unamplified LGSN; GPAm12/A-LG or A-LGSN = amplified (A) LG4 or LGSN.

\* and # indicate DNAs digested with *Nhe* I and *Xho* I, respectively. Relatively short exposures were done to include signals from single and multiple copy producers on the same film. Bands representing mouse GC were therefore not seen as in longer exposures.

B. Determination of viral titers on 3T3<sup>tk</sup> cells: GPAm12 producers A-LG4, A-LGSN, and LGSN (single proviral copy) were titrated on 3T3<sup>tk</sup> cells. DNA was extracted from 3T3<sup>tk</sup> cells 3 days after the infection and digested with *Nhe* I. A Southern blot was performed and the strength of the signal was compared with copy number controls (vector plasmid mixed with control 3T3<sup>tk</sup> cell DNA). The LGSN vector has a signal similar to that of the 1.0 copy control, but the amplified vectors A-LG4 and A-LGSN have a stronger signal and seem to have more than one copy per cell on average. The signal from the 0.1 copy is barely seen on this exposure. 3T3 neg are uninfected 3T3 cells.

**Table 1.** Transduction of human CD34<sup>+</sup> cells: comparison of producer cells with one or multiple proviral copies

Producers	Proviral copy number	3T3 titer	CD34 <sup>+</sup> titer (PCR analysis)
GPAm12/LGSN	1	1.5 × 10 <sup>7</sup>	25% (9/36)
GPAm12/A-LGSN	>5	1.0 × 10 <sup>8</sup>	41% (23/56) <sup>a</sup>
GPAm12/A-LG	>5	<sup>b</sup>	42% (15/36)

<sup>a</sup>Data obtained from five independent experiments; all others, from three.

<sup>b</sup>3T3 titer similar to A-LGSN as determined by Southern blot.

A = amplified vector producer with multiple viral copies.

A-LGSN. Both of these vectors and all others used in this study were tested for helper virus by the marker rescue assay and were found to be free of helper virus.

The amplified vectors were compared to GP+envAm12/LGSN, a producer cell line that has a single proviral copy for transduction efficiency on 3T3<sup>tk</sup> cells (Fig. 2B) and human CD34<sup>+</sup> progenitor cells. The copy number was less in 3T3<sup>tk</sup> cells with the LGSN vector than with the amplified ones, A-LGSN and A-LG4 (Fig. 2B). The transduction efficiency of CD34<sup>+</sup> cells was increased to approximately 40% (an average of three to five experiments) using the amplified vector producer cells (Table 1).

#### Transduction of LTCIC from Gaucher patients

The high-titer vectors used here transduce hematopoietic progenitor cells from patients with Gaucher disease and normal individuals with similar efficiency, irrespective of whether the initial target cells are MNBM cells or CD34<sup>+</sup> BM cells (data not shown). Therefore we pooled data from MNBM cells and CD34<sup>+</sup> BM cells. Viral supernatants from the two amplified viruses, A-LGSN and A-LG4, were used to

**Table 2.** Transduction of bone marrow cells from Gaucher patients

	CFU-C efficiency					
	Patient I <sup>a</sup>		Patient II <sup>a</sup>		Patient III <sup>b</sup>	
	P/T <sup>c</sup>	%	P/T <sup>c</sup>	%	P/T <sup>c</sup>	%
<b>Week 0</b>						
Uninfected	0/5	0	0/5	0	0/5	0
A-LG4	ND	ND	6/10	60	3/10	30
A-LGSN	5/10	50	—	—	4/10	40
<b>Week 3</b>						
Uninfected	0/5	0	0/5	0	0/5	0
A-LG4	ND	ND	—	—	3/10	30
A-LGSN	2/10	20	6/10	60	5/10	50
<b>Week 5</b>						
Uninfected	0/5	0	0/5	0	0/5	0
A-LG4	ND	ND	1/10	10	4/10	40
A-LGSN	3/10	30	3/10	30	5/10	50

<sup>a</sup>Ficoll gradient-enriched BM cells were used.<sup>b</sup>CD34<sup>+</sup> BM cells were used.<sup>c</sup>Positive/total assessed by PCR analysis of individual colonies derived from clonogenic assays of LTBM.

ND = not done; — = technical failure.


infect either MNBM cells or BM CD34<sup>+</sup> cells from patients with Gaucher disease and were cultured *in vitro* for 5 weeks. Cells were sampled at different time points. As shown in Table 2, analysis of clonogenic progenitors obtained immediately after infection or recovered from the 3-week-old LTBM, revealed high gene transfer efficiencies, mostly ranging from 20 to 60% (an average of 40%). Significantly, 32% of CFU-GM progenitors recovered from the 5-week-old culture contained the recombinant GC sequence (295 bp) (Fig. 3), indicating that amplified viruses can efficiently transduce long-term bone marrow culture initiating cells using the supernatant infection protocol.

#### Correction of the enzyme deficiency in Gaucher LTCIC following gene transfer


To test for vector expression in the progeny of primitive hematopoietic cells, mRNA was isolated at week 5 of LTBM from A-LGSN-transduced bone marrow cells of Gaucher

patient I. As shown in Figure 4, the expected 5.3-kb transcripts from the transduced recombinant retroviral vector A-LGSN could be detected using the GC-specific probe labeled with <sup>32</sup>P-dCTP.

MNBM cells and BM CD34<sup>+</sup> cells from Gaucher patients were cultured on irradiated heterologous stromal cells for 5 weeks after retroviral transduction. At week 0 (immediately after transduction), week 3, and week 5, cells were assayed for clonogenic progenitors, and after being in methylcellulose culture for 2 weeks, CFU-GM colonies were pooled to determine GC activity. The specific GC activity (nM/mg protein/min) from three different individuals is summarized in Table 3. All enzyme measurements were compared with the enzyme activity in normal control colonies (43 nM/mg protein/min, an average of several experiments). Considerable increases in GC activity of cells transduced by both A-LG4 and A-LGSN were seen in all three patient samples tested. These increases were seen at all time points sampled throughout the entire 5-week culture period. At 5 weeks postinfection, the enzyme levels in the progeny cells from progenitors harvested after 5 weeks of long-term culture were equal to or higher than levels found in asymptomatic heterozygous carriers (one exception: in patient II, vector LG-4 at 3 weeks was only 44% of control values). On average, the enzyme levels (A-LGSN) relative to control of normal BM cells were 84% at week 0, 70% at week 3, and 74% at week 5 (Table 3). Progenitors positive for the transferred GC gene were 45% (9/20) at week 0, 43% (13/30) at week 3, and 37% (11/30) at week 5 (Table 2), consistent with the level of enzyme activity, although the correlation was not perfect. The enzyme activity was measured in the progeny of clonogenic progenitors 7 weeks after the infection, not in the total nonadherent cell population as in a previous study [20]. The number of mature macrophages, harvested and dislodged from the LTC by pipette, increases with time (9% at week 0, 21% at week 3, and 29% at week 5 in one experiment), and macrophages tend to have higher GC enzyme activity per unit of protein than other hematopoietic cells (Correll et al., unpublished studies). Therefore the rise in enzyme activity will tend to be higher at 5 weeks than at week 0 when the gene transfer efficiency is the same at both time points and total nonadherent cells are measured. We did not compare the proportion of macrophages in the colonies derived from progenitors of LTC at weeks 0, 3, and 5 and can therefore not speculate whether



**Fig. 3.** Determination of GC gene transfer efficiency by PCR. CD34<sup>+</sup> cells were cultured in the presence of irradiated heterologous feeders for 5 weeks *in vitro* and harvested for CFU-GM assay in methylcellulose medium. Well-isolated single colonies were picked and processed for PCR. Lanes 1–5: non-transduced cells; lane 6: positive A-LGSN control; lanes 7–16: A-LG4-transduced cells. 761 bp and 295 bp = amplified DNA fragments from the genomic DNA and the transduced vector, respectively. +/- = presence or absence of the 295-bp DNA fragment. Four of 10 colonies picked in this experiment were positive for the vector.



**Fig. 4.** Expression of GC cDNA in A-LGSN-transduced MNBM cells from Gaucher patient I at week 5. MNBM cells were isolated, infected, and cultured in the presence of irradiated heterologous feeder cells for 5 weeks *in vitro*, and RNA from the cells was examined by Northern blot analysis (probed using  $^{32}$ P-labeled GC cDNA). A-LGSN = total cellular RNA extracted from a producer cell line A-LGSN; Pat I/A-LGSN and Pat I/control = RNA from A-LGSN-transduced and from the nontransduced BM cells of Patient I, respectively. The expected size of the transcript is 5.3 kb.

differential composition of progeny cells in the colonies from different time points may have affected the enzyme values.

## Discussion

We have efficiently transferred the human GC cDNA into mononuclear BM cells and CD34<sup>+</sup> BM cells from Gaucher type I patients using supernatants from the amplified amphotropic retroviral producer cell lines A-LGSN and A-LG4. These transduced cells initiated and maintained long-term bone marrow cultures in the presence of irradiated heterogeneous bone marrow fibroblast feeders, and sustained GC enzyme production was demonstrated until the culture was terminated at week 5. Since the enzyme activity was measured in pooled colonies derived from hematopoietic progenitors harvested after 5 weeks of long-term culture, we conclude that efficient transduction of LTCIC from Gaucher patients has been achieved and that the enzyme deficiency as measured in their progeny cells has been corrected.

Gene transfer into HSC has been problematic, since these cells are rare in BM [37] and mostly quiescent [38]. Several approaches have been developed to maximize transduction efficiency of the HSC, such as use of hematopoietic growth factors during infection [28,39-44], better vector design [9,45], the use of coculture instead of supernatant infection, amplification of copy number in producer cell lines [23,24,26], and purification of CD34<sup>+</sup> cells to increase the

**Table 3.** GC activity of transduced BM cells from Gaucher patients

	nM/mg protein/min (avg $\pm$ SD)			Average
	Patient I	Patient II	Patient III <sup>a</sup>	
<b>Week 0<sup>b</sup></b>				
Uninfected	11.7 $\pm$ 0.8	17.8 $\pm$ 0.7	17.1 $\pm$ 1.1	15.6 (36%) <sup>c</sup>
A-LG4	ND	37.6 $\pm$ 2.8	32.9 $\pm$ 5.5	35.3 (82%)
A-LGSN	22.2 $\pm$ 1.4	41.1 $\pm$ 2.5	45.3 $\pm$ 4.1	36.2 (84%)
<b>Week 3</b>				
Uninfected	13.1 $\pm$ 2.7	9.1 $\pm$ 1.2	12.4 $\pm$ 0.4	11.5 (27%)
A-LG4	ND	22.6 $\pm$ 1.4	25.4 $\pm$ 1.0	24.0 (56%)
A-LGSN	26.8 $\pm$ 2.3	30.8 $\pm$ 3.9	32.5 $\pm$ 3.4	30.1 (70%)
<b>Week 5</b>				
Uninfected	16.7 $\pm$ 2.6	12.0 $\pm$ 0.3	18.2 $\pm$ 1.4	15.7 (36%)
A-LG4	ND	18.8 $\pm$ 2.5	33.0 $\pm$ 4.4	25.9 (60%)
A-LGSN	29.9 $\pm$ 1.1	28.4 $\pm$ 3.2	36.8 $\pm$ 1.3	31.7 (74%)

<sup>a</sup>CD34<sup>+</sup> cells used in this experiment.

<sup>b</sup>GC activity measured in triplicate by pooling of CFU-GM colonies from one patient and SD calculated with  $n=3$ . GC activity in the normal control in the week 0: 43.03 nM/mg protein/min on average.

<sup>c</sup>Percentage in parentheses: GC activity relative to an average of the normal control.

vector-to-target ratio [46]. To increase transduction efficiency of human hematopoietic cells without having to use a coculture procedure, we constructed amplified retroviral producer cell lines containing multiple proviral copies to increase viral titer. Our experiments clearly indicate that multiple viral copies in the producer cells will increase their ability to transduce human hematopoietic progenitors. The level of gene transfer efficiency into LTCIC achieved approximately 40%, similar to the percentage level of chimerism that exists in at least one Gaucher patient who has undergone transplantation and has improved clinically [47]. Our data suggest that efficient supernatant infection can be achieved with high-titer retroviral producer cells, consistent with a recent report by Hughes et al. [28]

Use of supernatant infection instead of coculture may be more easily justified in the setting of clinical gene therapy than cocultivation of human BM cells with murine retroviral producer cells. Techniques using transformed mouse cells in coculture with hematopoietic cells are not considered safe for human gene therapy, since a fraction of the mouse cells would likely be transplanted together with the hematopoietic cells of a patient and possibly pose complications to the patient. Although the use of autologous stromal cells to increase gene transfer efficiency by viral supernatants [21] is a possibility<sup>1</sup> it would be preferable and much simpler technically to use a stroma-free supernatant transduction protocol.

Nolta et al. [20] used a coculture transduction protocol to correct the enzyme deficiency in hematopoietic cells of a Gaucher patient. Nonadherent cells from a long-term culture were harvested 4 weeks after the infection to demonstrate the

<sup>1</sup>Recombinant DNA Advisory Committee (RAC) has already approved supernatant transduction protocol with autologous stroma. The RAC has also approved the use of packaging cells with multiple proviral copies to increase viral titer in supernatants for clinical gene therapy experiments including a supernatant transduction protocol using an amplified LG vector producer cell line from this laboratory.



correction of the enzyme deficiency compared to control cultures. The enzyme was measured in all the nonadherent cells in the culture, including all the mature cells derived from progenitors that are less primitive than LTCIC. It was therefore impossible to demonstrate decisively successful gene transfer into LTCIC. Our goal was to demonstrate whether correction of the enzyme deficiency in hematopoietic cells of Gaucher patients could be achieved using a clinically acceptable supernatant transduction protocol and whether this protocol could be used to transduce LTCIC efficiently and correct the enzyme deficiency in their progeny cells. Therefore we measured enzyme activity in hematopoietic colonies derived from progenitors that were harvested from the long-term culture up to 5 weeks following the transduction. Enzyme measurements were therefore done after culture up to 7 weeks (2 weeks in methylcellulose) after the transduction. The progeny cells of the last time point should therefore all be derived from LTCIC. Correction of the enzyme deficiency was demonstrated at all time points (Table 3), and the enzyme measurements correlated relatively well with the transduction efficiency as determined by PCR analysis of CFU-GM colonies.

It is encouraging that the overall enzyme activities following gene transfer are well above the average enzyme activity of asymptomatic heterozygotes and this includes the last time point designed to measure gene transfer into LTCIC. However, it is unclear whether this would be sufficient to cure Gaucher disease. Asymptomatic heterozygotes have approximately 50% of the normal GC enzyme activity in every cell. In our experiment, 40% of the cells contain GC activity that is at normal or even higher levels, while the remaining 60% are genetically unmodified and have low enzyme activity. Since the enzyme is a membrane-bound glycoprotein that is not secreted from the cell to any extent, it is unlikely that the enzyme produced in corrected cells will have direct effects on uncorrected cells. Despite these considerations, it is interesting to note that the Gaucher patients who have undergone allogeneic transplantation with incomplete engraftment resulting in stable chimerism have improved clinically [47], but detailed studies on the extent of their chimerism, resolution of pathological changes, and clinical follow-up have not been reported to our knowledge. It is possible that lipid-laden macrophages may eventually die and the lipid may then be engulfed by normal or gene-corrected macrophages. If that is the case, the percentage of gene-corrected macrophages required for clinical improvement is considerably less than 100%.

While the LTCICs that have been transduced are primitive multipotential cells, they cannot be claimed to be repopulating hematopoietic stem cells. To assay the latter cells, transplantation studies have to be performed in xenograft models or large animals or in phase I clinical trials. These studies may help to answer questions not easily addressed by in vitro experiments.

In summary, we have created high-titer amphotropic retroviral producer cell lines using either coculture or repetitive supernatant infection. Our results demonstrate that supernatants from these amplified producer cell lines can efficiently transduce LTCIC from bone marrow of Gaucher patients and that potentially therapeutic levels of GC enzyme production are achieved in their progeny cells.

### Acknowledgments

We would like to thank Dr. Roscoe O. Brady for support and encouragement, Dr. R.K. Humphries for his advice during this study and his invaluable critical reading of this manu-

script, R.K.H. Connie Eaves, and Karen Lambie for sharing their expertise in performing LTBMCM with us so as to make this study possible, Dr. Robert E. Donahue and Earl West for hematological staining and differential counting, and Immunex Corporation for growth factors.

### References

1. Brady RO, Kanfer JN, Shapiro D (1965) Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher disease. *Biochem Biophys Res Commun* 18:221
2. Barranger JA, Ginns EI (1989) Glucosylceramide lipidoses: Gaucher diseases. In: CR Scriver, AL Beaudet, WS Sly, D Valle (eds) *The Metabolic Basis of Inherited Disease*. New York: McGraw-Hill, 1677
3. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO (1990) Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. *Proc Natl Acad Sci USA* 87:1913
4. Barton NW, Brady RO, Dambrosia JM, Doppelt SH, Hill SC, Holder CA, Mankin HJ, Murray GJ, Zirzow GC, Parker RI (1992) Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease. *J Pediatrics* 120:277
5. Beutler E, Kay A, Saven A, Garver P, Thurston D, Dawson A, Rosenbloom B (1991) Enzyme replacement therapy for Gaucher disease. *Blood* 78:1183
6. Ringden O, Groth C, Erikson A, Backman L, Granqvist S, Mansson J, Svennerholm L (1988) Long-term follow-up of the first successful bone marrow transplantation in Gaucher disease. *Transplantation* 46:66
7. Hobbs JR, Shaw PJ, Hugh Jones K, Lindsay I, Hancock M (1987) Beneficial effect of pre-transplant splenectomy on displacement bone marrow transplantation for Gaucher syndrome. *Lancet* 1:1111
8. Beutler E (1992) Gaucher disease: new molecular approaches to diagnosis and treatment. *Science* 256:794
9. Karlsson S (1991) Treatment of genetic defects in hematopoietic cell function by gene transfer. *Blood* 78:2481
10. Miller AD (1992) Human gene therapy comes of age. *Nature* 357:455
11. Anderson WF (1992) Human gene therapy. *Science* 256:808
12. Nolte JA, Sender LS, Barranger JA, Kohn DB (1990) Expression of human glucocerebrosidase in murine long-term bone marrow cultures after retroviral vector-mediated transfer. *Blood* 75:787
13. Correll PH, Fink JK, Brady RO, Perry LK, Karlsson S (1989) Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells. *Proc Natl Acad Sci USA* 86:8912
14. Correll PH, Kew Y, Perry LK, Brady RO, Fink JK, Karlsson S (1990) Expression of human glucocerebrosidase in long-term reconstituted mice following retroviral-mediated gene transfer into hematopoietic stem cells. *Hum Gene Therapy* 1:277
15. Weinthal J, Nolte JA, Yu XJ, Liller J, Uribe L, Kohn DB (1991) Expression of human glucocerebrosidase following retroviral vector-mediated transduction of murine hematopoietic stem cells. *Bone Marrow Transplant* 8:403
16. Karlsson S, Correll PH, Xu LC (1993) Gene transfer and bone marrow transplantation with special reference to Gaucher's disease. *Bone Marrow Transplant* 11 (suppl 1):124
17. Ohashi I, Boggs S, Robbins P, Bainson A, Patrene K, Wei FS, Li J, Lucht L, Fei Y, Clark S, Kimak M, He H, Mowery-Rushton P, Barranger JA (1992) Efficient transfer and sus-

- tained high expression of the human glucocerebrosidase gene in mice and their function macrophages following transplantation of bone marrow transduced by a retroviral vector. *Proc Natl Acad Sci USA* 89:11332
18. Correll PH, Colilla S, Dave HPG, Karlsson S (1992) High levels of human glucocerebrosidase activity in macrophages of long-term reconstituted mice after retroviral infection of hematopoietic stem cells. *Blood* 80:331
  19. Fink JK, Correll PH, Perry LK, Brandy RO, Karlsson S (1990) Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease. *Proc Natl Acad Sci USA* 87:2334
  20. Nolte JA, Yu XJ, Bahner I, Kohn DB (1992) Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow. *J Clinical Investigation* 90:342
  21. Moore KA, Deisseroth AB, Reading CL, Williams DE, Belmont JW (1992) Stromal support enhances cell-free retroviral vector transduction of human bone marrow long-term culture initiating cells. *Blood* 79:1393
  22. Freas DL, Correll PH, Dougherty SF, Karlsson S, Pluznik DH (1993) Evaluation of expression of transferred genes in differentiating myeloid cells: expression of human glucocerebrosidase in murine macrophages. *Human Gene Ther* 4:283
  23. Bestwick RK, Kozak SL, Kabat DK (1988) Overcoming interference to retroviral superinfection results in amplified expression and transmission of cloned genes. *Proc Natl Acad Sci USA* 85:5404
  24. Bodine DM, McDonagh KT, Brandt SJ, Ney PA, Agricola B, Byrne E, Nienhuis AW (1990) Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. *Proc Natl Acad Sci USA* 87:3738
  25. Danos O, Mulligan RC (1988) Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. *Proc Natl Acad Sci USA* 85:6460
  26. Lynch CM, Miller AD (1991) Production of high-titer helper virus-free retroviral vectors by cocultivation of packaging cells with different host ranges. *J Virol* 65:3887
  27. Folks TM, Kessler SW, Orenstein JM, Justement JS, Jaffe ES, Fauci AS (1988) Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. *Science* 242:919
  28. Hughes PFD, Thacker JD, Hogge D, Sutherland HJ, Thomas TE, Lansdorp PM, Eaves CJ, Humphries RK (1992) Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures. *J Clin Invest* 89:1817
  29. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ (1990) Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. *Proc Natl Acad Sci USA* 87:3584
  30. Higuchi R (1989) Simple and rapid preparation of samples for PCR. In: HA Erlich (ed) *PCR Technology: Principles and Applications for DNA Amplification*. New York: Stockton Press, 31
  31. Xu LC, Bresnick E (1990) Induction of cytochrome P450IA1 in rat hepatoma cells by polycyclic hydrocarbons and a dioxin. *Biochem Pharmacol* 40:1399
  32. Xu LC, Sinclair P, Bresnick E (1993) Induction of endogenous cytochrome P450IA1 and its recombinant construct in a rat hepatoma cell line by polycyclic hydrocarbons and a dioxin. *Int J Biochem* 25:13
  33. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72:248
  34. Miller AD, Buttimore C (1986) Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. *Mol Cell Biol* 6:2895
  35. Markowitz D, Goff S, Bank A (1988) Construction and use of a safe and efficient amphotropic packaging cell line. *Virology* 167:400
  36. Markowitz D, Goff S, Bank A (1988) A safe packaging line for gene transfer: separating viral genes on two different plasmids. *J Virol* 62:1120
  37. Spangrude GJ, Heimfeld S, Weissman IL (1988) Purification and characterization of mouse hematopoietic stem cells. *Science* 241:58
  38. Harrison DE, Astle CM, Lerner C (1988) Number and continuous proliferative pattern of transplanted primitive immunohematopoietic stem cells. *Proc Natl Acad Sci USA* 85:822
  39. Eglitis MA, Kantoff PW, Kohn DB, Karson E, Moen RC, Lothrop CD, Jr, Blaese RM, Anderson WF (1988) Retroviral-mediated gene transfer into hemopoietic cells. *Advances Exp Med Biol* 241:19
  40. Bodine DM, Karlsson S, Nienhuis AW (1989) Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells. *Proc Natl Acad Sci USA* 86:8897
  41. Gelinas RE, Bender MA, Miller AD (1989) Regulated expression of the human beta-globin gene after retroviral transfer into murine and human hematopoietic cells. *Progress Clin Biol Res* 1316B:235
  42. Luskey BD, Lim B, Apperley JF, Orkin SH, Williams DA (1990) Gene transfer into murine hematopoietic stem cells and bone marrow stromal cells. *Ann N Y Acad Sci* 612:398
  43. Luskey BD, Rosenblatt M, Zsebo K, Williams DA (1992) Stem cell factor, interleukin-3, and interleukin-6 promote retroviral-mediated gene transfer into murine hematopoietic stem cells. *Blood* 80:396
  44. Hughes PFD, Eaves CG, Hogge DE, Humphries RK (1989) High-efficiency gene transfer to human hematopoietic cells maintained in long-term marrow culture. *Blood* 74:1915
  45. Miller AD, Rosman GI (1989) Improved retroviral vectors for gene transfer and expression. *Biotechniques* 7:980
  46. Donahue RE, Kessler SW, Bodine D, McDonagh K, Dunbar C, Goodman S, Agricola B, Byrne E, Raffeld M, Moen R, Bacher J, Zsebo KM, Nienhuis AW (1992) Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. *J Exp Med* 176:1125
  47. Ringden O, Groth CG, Aschan J, Bome P, Ljungman P, Lonnqvist B, Malm G, Mansson JE, Shanwell A, Svennerholm L, Tolleran J, Winiarski J (1990) Bone marrow transplantation for metabolic disorders at Huddinge Hospital. *Transplant Proc* 22:198

Distribution/Availability Codes

Dist	Avail and/or Special
------	----------------------

A-1	20
-----	----